⌕
ArriVent BioPharma · AVBP · Nasdaq
Tenet 69 · Solid
Compare
$10.69−7.53%At closeTenet 69 · Solid
$10.69−0.87 (−7.53%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

ArriVent BioPharma (AVBP) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

5 figures withheld by our checks. Each blank figure names its reason.

Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld.
The lines that matter · FY23–FY25
Revenue ($M)—
0.0
FY23→FY25CAGR —
Net income ($M)▼106.6%
−166.3
FY23→FY25CAGR —
Diluted EPS▼68.8%
−4.32
FY23→FY25CAGR —
What the income statement says · FY23–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−153.4R&D−24.2SG&A−177.5Op income11.2Tax & other−166.3Net income

Margin trend · direction beats level
108530%sector median net margin ~3%FY23FY25

This filer reports no gross profit or operating income line, so those margins are not drawn.

The receipt · income statement · FY23–FY25 USD millions except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7766, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23YoYCAGR 23→25
Revenue & profitability
Revenue
5.00.00.00.0——
Cost of revenue
—0.00.00.0——
Gross profit
—A0.00.00.0——
Research & development
151.0153.479.064.9▲94.1%+53.7%
Selling, general & admin
35.024.215.39.7▲58.0%+57.8%
Total operating expenses
186.0177.594.374.6▲88.2%+54.3%
Operating incomefeeds ROC rank
−181.0−177.5−94.3−74.6▼88.2%—
Other income, net
11.911.213.85.3——
Pretax income
−169.1−166.3−80.5−69.3▼106.6%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−169.1−166.3−80.5−69.3▼106.6%—
Per share
Diluted EPSbuyback-sensitive
−3.51−4.32−2.56−32.38▼68.8%—
Diluted shares (mn)
49.5338.4631.472.14▲22.2%+323.9%
Margins
Gross margin
—A—————
Operating margin
−3620.0%—————
Net margin
−3381.4%—————
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
CSV export is on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-05 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.